SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 
Home Editorial ethics For authors Current issue Archive Contacts

No1-2(3) 2020

Back to the issue


DOI 10.37219/2528-8253-2020-1-16
Kovtunenko ОV, Timchuk SM, Sport’ko BV
Matrix metalloproteinases and inhibitors of matrix metalloproteinas as markers of laryngeal cancer metastases
Kovtunenko Alexander Vasilievich
State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine"
Professor of the Department of Otolaryngology
Doctor of Medical Sciences
Email: lor@dsma.dp.ua
Orchid ID: https://orcid.org/0000-0002-0562-7684

Tymchuk Sergey Nikolaevich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov» Dnipropetrovsk Regional Council
Head of the Department of Otorhinolaryngology No. 2 (oncological)
Doctor of Medical Sciences
Email: sergej_lor@ukr.net
Orchid ID: https://orcid.org/0000-0002-8706-2313

Shportko Bogdan Viktorovich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov» Dnipropetrovsk Regional Council
Department of Otorhinolaryngology No. 2 (oncological)
Otolaryngologist
Email: bogdan.shportko@gmail.com
Orchid ID: https://orcid.org/0000-0002-4242-2784

Abstract

Topicality: Today, laryngeal cancer occupies an important place in the structure of tumors of the head and neck. The survival rate of patients with laryngeal cancer remains unchanged for a longtime. One of the main mechanisms of tumor growth and metastasis is invasion into the surrounding tissues, followed by the expansion of  tumor cells. This process is regulated by a system of enzymes – matrix metalloproteinases (MMP) and their inhibitors – tissue inhibitors of matrix metalloproteinases (TIMP).
Aim: To study the in formativeness of immunohistochemical study and determining of the expression of  molecular markers MMP-1; MMP-9; TIMR-1 and TIMR-2 in patients with laryngeal cancer, to determine the possibility of predicting regional metastases and recurrences.
Materials and methods: 70 patients with laryngeal cancer of III-IV stages (T3-4N0-3M0) and II clinical group were understudy. Of these, 39 patients from the main group had regional metastases of laryngeal cancer, in 31 patients of the comparison group regional metastases were not detected. The age of patients ranged from 33 to 74 years. The average age of patients was 61.9 years. Male patients made up an absolute majority of 99% (No=69). All patients were histologically diagnosed with squamous cell carcinoma. Monoclonal antibodies to MMP-1 were used as primary molecular markers; MMP-9 as well as TIMP-1 and TIMP-2 (Termo Scientific, USA). In evaluating IHC reactions with the marker, the expression was calculated as the percentage of cells with a cytoplasmic reaction at increased (Ч 400) in 4 gradations: (1+) - <10%, (2+) - from 10% to 50%, (3+) - from 51% to 100%. The expression of TIMP1 and TIMP2 was assessed as negative with a percentage of stained cells <30%, “-” - 0, and > 30% as “+” - 1.
Results: Statistically significant difference in the expression of MMP-1 and MMP-9 between the groups in the presence of metastases (p <0.01) was revealed: patients with metastases were more likely to have moderate (++) and high (+++) expression of biomarkers, and rarely - low expression (+). Positive TIMP-2 was significantly more common among patients with metastases (p = 0.05).
MMP-1 and TIMP-2 were significant predictors of metastasis (Table 2). Increase in the expression of MMP-1 by one category increased the chances of metastasis almost by 5 times (OR = 4.75 (95% CI 1.77 – 14.75)). In positive TIMP-2, the chances of tumor metastasis were by 2.7 times higher (95% CI 1.01 – 7.89) than with negative TIMP-2. The difference between the ROC curves for MMP-1 and TIMP-2 was not statistically significant (p = 0.30). Expression of any of the indicators did not allow predicting the recurrence of the disease.
The inclusion of age in the regression model did not have a positive effect on the prognostic ability of predictors.
Conclusion: Expression rates of molecular markers MMP-1, MMP-9, TIMP-1 and TIMP-2 were statistically associated with the degree of tumor differentiation (p <0.05). According to the results of statistical data processing, MMP-1 and TIMP-2 were significant predictors of metastasis (p <0.01). Increase in the expression of MMP-1 to a positive or high level increased the chances of metastasis by 5 times (OR = 4.75 (95% CI 1.77 – 14.75). In positive TIMP-2 the chances of tumor metastasis were by 2.7 times higher) (95% CI 1.01 -7.89 ) than in the negative.

Keywords

laryngeal cancer, metastases, immunohistochemical study, matrix metalloproteinases, matrix metalloproteinase inhibitors.


Reference

  1. Akashi M, Hisaka T, Sakai H, Ishikawa H, Kawahara R, Goto Y, et al. Expression of matrix metalloproteinases in intraductal papillary mucinous neoplasm of the pancreas. Anticancer Res. 2019 Aug; 39: 4485-90. doi: 10.21873/ anticanres.13623.
  2. Barnes L, Eveson JW, Richard P, Sidransky D. World Health Organization Classification of Tumours: pathology and genetics of head and neck tumours. Lyon, France: IARC Press; 2005. 430 p.
  3. Bodnar M, Szylberg L, Kazmierczak W, Marszalek A. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors. Journal of Oral Pathology & Medicine. 2015 Jul; 44(6): 437-43. doi: 10.1111/jop.12270.
  4. Bradford CR, Kumar B, Bellile E, Lee J, Tailor J, D’Silva N, et al. Biomarkers in Advanced Larynx Cancer Laryngoscope. 2014 Jan; 124(1): 179-87. doi: 10.1002/lary.24245.
  5. Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect
    increased tumor invasiveness. BMC Cancer.2004Aug;4:42. doi:10.1186/1471-2407-4-42.
  6. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep; 44(3):837-45.
  7. Gou XX, Jin F, Chen HX, Wu WL, Chen L, Zeng Y. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and clinical significance.
    Zhonghua Yi Xue Za Zhi. 2010 May;90(18):1264-7. doi: 10.1007/s12253-013-9720-3.
  8. Grunnet M, Mau-Sorensen M, Brunner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013 Aug;48:899-905.doi: 10.3109/00365521.2013.812235.
  9. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 2000; 36: 207-13.
  10. Jiang Y, Goldberg ID, Shi YE. Complex roles of  tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002 Mar; 21: 2245-52.
    doi: 10.1038/sj.onc.1205291.
  11. Kariche N, Hortal MT, Benyahia S, Alemany L, Moula N, Clavero O. Comparative assessment of  HPV, alcohol and tobacco etiological fractions in
    Algerian patients with laryngeal squamous cell carcinoma. Infect Agent Cancer. 2018 Mar; 13: 8. doi: 10.1186/s13027-018-0181-x.
  12. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010 Apr; 141(1): 52-67.
    doi: 10.1016/j.cell.2010.03.015.
  13. Korampalli TS, Stafford ND. Expression of angiogenic growth factors in laryngeal carcinoma. Molecular and Clinical Oncology.2013 Nov;1(6):
    1013-8. https://doi.org/10.3892/mco.2013.179.
  14. Kozlowski M, Laudanski W, Mroczko B, Szmitkowski M, Milewski R, Lapuc G. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci. 2013 June; 18(2):1-8.
    doi: 10.2478/ams-2013-0017.
  15. Li M, Tian L, Ren H, Chen X, Wang Y, Ge J, et al. MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8. J Transl Med. 2015 Aug; 13: 271. doi: 10.1186/s12967-015-0626-6.
  16. Oblak I, Velenik V, Anderluh F, Mozina B, Ocvirk J. The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapyin patients with rectal cancer. Radiol Oncol. 2013; 47: 138-44.
    doi:10.2478/raon-2013-0028.
  17. Olszewska E, Matulka M, Mroczko B, Pryczynicz A, Kemona A, Szmitkowski M,Mierzwinski Jet al. Diagnostic value of matrix metalloproteinase 9 and
    tissue inhibitor of matrix metalloproteinases 1 in cholesteatoma. Histology and Histopathology. 2016 Mar; 31(3): 307-15.
    doi: 10.14670/HH-11-677.
  18. Robbins KT, Ferlito A, Shah JP, Hamoir M, Takes RP, Strojan P, et al. The evolving role of selective neck dissection for head and neck squamous cell
    carcinoma. Eur Arch Otorhinolaryngol. 2013 Mar; 270(4): 1195-202. doi: 10.1007/s00405-012-2153-x
  19. Shimizu Y, Kondo S, Shirai A, Furukawa M, Yoshizaki T. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer Auris Nasus Larynx. 2008 Sep; 35(3): 381-9. doi: 10.1016/j.anl.2007.12.002.
  20. Simundiс A.M. Measures of Diagnostic Accuracy: Basic Definitions EJIFCC. 2009 Jan; 19(4): 203-11.
  21. Uloza V, Liutkevicius V, Pangonyte D, Saferis V, Lesauskaite V. Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels. European Archives of Oto-Rhino-Laryngology. 2011; 268(6): 871–878.
    doi: 10.1007/s00405-011-1494-1
  22. Wu TY, Zhang TH, Qu LM, Feng JP, Tian LL, Zhang BH, et al. MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression. Int J Clin Exp Pathol. 2013 Dec; 7(1): 56-63.
  23. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node me-
    tastases. Laryngoscope. 2004 Dec; 114(12): 2243-8. doi: 10.1097/01.mlg.0000149467.18822.59.
  24. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. Journal of Biochemistry and Molecular Biology. 2003; 36(1): 128-37. doi: 10.5483/bmbrep.2003.36.1.128.
  25. Yoshizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001; 95: 44-50.
    doi: 10.1002/1097-0215 (20010120)95:1<44::AID-IJC1008>3.0.CO;2-M.
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»